Heart disease is the leading cause of death in this country [1]. Most of us will lose someone to it. Many of us already have.

If you are an interventional cardiologist, an interventional radiologist, or a vascular surgeon, you have seen this from the closest possible vantage point. The patient on the table whose anatomy will not give up its secret. The decision made on inference because the imaging would not show you what you needed to see. The case that ended one way when, with better information, it might have ended another.

That is the part of medicine that deserves a different bet. And what I want to do here is explain why, after 35 years of backing technology in other fields, I made one.

The shape I look for as an investor.

I started my career in software infrastructure at Microsoft, doing business in more than 50 countries. I founded a mining and exploration company that took a $500K seed to a $160M market cap. I have raised more than $95M across the companies I have built. I have an angel portfolio with returns I am proud of.

I am not a MedTech specialist. That is a feature, not a bug.

A broad investor sees the same shape across markets. You learn that the patterns of success and failure repeat across industries with surprising fidelity. A real problem. An asymmetric solution. A team that understands what it takes to get from where they are today to where the problem actually gets solved.

When all three line up, you back it. The market the team is operating in becomes secondary. What matters is the shape.

The shape I see at VerAvanti is a question.

What if you could look inside an artery the way you look at anything else? Not interpret a grainy ultrasound. Not mentally reconstruct a black-and-white cross section. Not require years of training to know what you are looking at.

What if you could just see it. The way you see anything else with your own eyes.

That is the question the Scanning Fiber Endoscope is built to answer. The optical architecture, invented at the University of Washington under Professor Eric Seibel, has been in development for more than two decades. The team at VerAvanti has spent the last several years translating that science into a clinical-grade device. The work that remains is real, and we are doing it.

Asymmetric bet, defined. The downside is the work, the time, and the regulatory pathway, all of which we have a credible plan for. The upside, if we get there, is a different relationship between a clinician and what they can see in the human body. That is not an incremental improvement. That is a category.

What doing the work actually looks like.

A real bet earns the right to be made by the work that surrounds it. Conviction is the easy part. Conviction without execution is a pitch deck.

Here is the operating picture at VerAvanti right now.

We model the company we are building, not the company we are pitching. The financial architecture, the use-of-proceeds discipline, the multi-region commercial sequencing, the year-by-year clinical and regulatory milestones — they live in one integrated picture, owned by the team that has to execute against it. The signal is not that the plan exists. The signal is that the plan is the working document.

The science behind SFE was invented at the University of Washington under Professor Eric Seibel, who continues today as Chief Scientific Officer. The work has been refined for two decades across federal grant funding, peer-reviewed publication, and successive engineering generations. The clinical advisory work is led by interventionalists who will use the device, not by consultants who will not. That is a deliberate choice. The company is being built by the people who care most about the answer.

We are building international commercial infrastructure now, before we need it — across North America, Europe, the Gulf, Latin America, and Asia. Reimbursement strategy is mapped country by country against innovation pathways that already exist.

The principle is simple: commercial readiness is a years-long build, not a launch-day decision.

The platform is protected by an active intellectual property portfolio across the United States, Europe, and Japan. The company is investing in artificial intelligence capability that will compound with every procedure the platform is part of, and in cybersecurity infrastructure built to the FDA's Section 524B requirements for connected medical devices. Defensibility is the work you do before anyone is watching.

These are not separate workstreams. They are one operating picture, executed by a team that is in this for the answer, not the announcement.

What becomes possible.

If we succeed, what becomes possible is not a feature.

It is a different conversation in the room. A different decision on the table. A different day for the patient who came in afraid.

It is a clinician who walks out of a case knowing they had the information they needed, instead of the information they could get. It is a procedure where the imaging answered the question instead of asking another one. It is a patient experience defined less by what was unknown and more by what was understood.

This is what the team is building toward. None of it is here today. All of it is the point.

The personal reason.

The business reason for joining VerAvanti is the asymmetric bet. The personal reason is simpler.

Most of us will lose someone to heart disease. Many of us already have. I have. The thing that drives every weekend hour and every red-eye flight and every difficult conversation is the unreasonable hope that, somewhere ahead of us, on a Tuesday afternoon, an interventionalist is going to look inside an artery and know exactly what they are looking at. And a patient is going to go home to their kids who otherwise wouldn't have.

That is the company we are building.

The imaging stopped me in my tracks the first time I saw it.

The technology is how we will scale it.

The patient is why.

References

[1] Centers for Disease Control and Prevention. Heart Disease Facts. Available at cdc.gov.